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Objective: To investigate dopamine D2/D3 receptor availability following traumatic brain injury (TBI) and their
relationship to the presence of DSM-IV Major Depressive Disorder (MDD) and patterns of axonal injury.
Methods: Twelve moderate-severe TBI patients and 26 controls were imaged using [11C]PHNO positron emission
tomography (PET) and structural magnetic resonance imaging (MRI). TBI patients and a second group of 32
controls also underwent diﬀusion tensor imaging (DTI) and neuropsychological assessment. Patients included six
with post-injury MDD (TBI-MDD) and six without (TBI-NON). Non-displaceable binding potential (BPND) [11C]
PHNO values were used to index D2/D3 receptor availability, and were calculated using a reference region
procedure. Diﬀerences in BPND were examined using voxelwise and region-of-interest analyses. White matter
microstructure integrity, quantiﬁed by fractional anisotropy (FA), was assessed and correlated with BPND.
Results: Lower [11C]PHNO BPND was found in the caudate across all TBI patients when compared to controls.
Lower [11C]PHNO BPND was observed in the caudate of TBI-MDD patients and increased [11C]PHNO BPND in the
Amygdala of TBI-NON patients compared to controls. There were no signiﬁcant diﬀerences in [11C]PHNO BPND
between TBI-MDD and TBI-NON patients. Furthermore, DTI provided evidence of axonal injury following TBI.
The uncinate fasciculus and cingulum had abnormally low FA, with the uncinate particularly aﬀected in TBI-
MDD patients. Caudate [11C]PHNO BPND correlated with FA within the nigro-caudate tract.
Conclusions: [11C]PHNO BPND is abnormal following TBI, which indicates post-traumatic changes in D2/D3
receptors. Patterns of [11C]PHNO BPND seen in patients with and without MDD suggest that further research
would be beneﬁcial to determine whether the use of dopaminergic treatment might be eﬀective in the treatment
of post-traumatic depression.
1. Introduction
Traumatic brain injury (TBI) often leads to cognitive and psychiatric
problems (Whitnall et al., 2006; Fleminger and Ponsford, 2005). These
are associated with dopaminergic abnormalities, including direct da-
mage to dopaminergic nuclei, axonal injury to dopaminergic neurons
and subsequent changes in dopamine production, metabolism and
clearance (Jenkins et al., 2016; Bales et al., 2009). Neuroimaging stu-
dies of the human dopaminergic system after TBI have been limited.
Striatal dopamine transporter (DAT) levels can be reduced (Wagner
et al., 2005; Donnemiller et al., 2000; Wagner et al., 2014), with as-
sociated damage within the substantia nigra (SN) and nigrostriatal
projections (Jenkins et al., 2018). Previous imaging studies have only
investigated D2 receptors, with variable results (Donnemiller et al.,
2000, Wagner et al., 2014). [11C]PHNO PET allows D2 and D3 re-
ceptors to be measured in vivo (Searle et al., 2010; Tziortzi et al., 2011),
providing a more detailed characterization of post-traumatic dopamine
receptor abnormalities.
Changes in dopaminergic function may be relevant to post-trau-
matic depression, which is very common (Jorge et al., 1993). Around a
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third of TBI patients develop major depressive disorder (MDD), with the
risk increasing with greater injury severity (Kreutzer et al., 2001). De-
pression often hinders recovery and leads to long-term morbidity
(Dikmen et al., 2003), but biological causes of MDD after TBI have
seldom been investigated. In studies of non-traumatic MDD, alterations
in dopamine receptors have been shown to be related to depressive
symptoms (D'Haenen and Bossuyt, 1994) and abnormalities within the
limbic system have often been observed (Drevets et al., 2008). High
levels of D3 receptors are seen in limbic structures (Murray et al., 1994)
and potentially play an important role in the development of neu-
ropsychiatric disorders (Sokoloﬀ et al., 2006). Hence, [11C]PHNO has
the potential to clarify the aetiology of post-traumatic depression and
inform a more targeted approach to treating this disabling condition.
Here we used [11C]PHNO PET to measure D2/D3 receptor avail-
ability following TBI. We tested the hypothesis that TBI patients would
show abnormalities of [11C]PHNO binding and that patients with and
without MDD will show distinct binding patterns. We used structural
MRI to examine grey matter volume changes using voxel-based mor-
phometry (VBM) to examine the relationship to D2/D3 receptor avail-
ability and diﬀusion tensor imaging (DTI) to investigate axonal injury
and its relationship to D2/D3 receptor availability.
2. Material and methods
2.1. Study design and participants
Twelve TBI patients with a single moderate-severe TBI, as classiﬁed
by the Mayo criteria (Malec et al., 2007), were assessed using [11C]
PHNO PET, structural T1 MRI, DTI and neuropsychological tests in this
cross-sectional study. A comparative group of 26 age-matched healthy
controls were also assessed using [11C]PHNO PET and structural T1
MRI. For comparison of DTI, grey matter (GM) volume and cognitive
performance, a second age-matched control group were recruited
(n=32). Demographics of healthy controls can be found in appendix
Table B.1. Patients and controls were carefully selected to avoid the
potential confound of medications. Speciﬁcally, individuals were not on
any medication known to aﬀect dopaminergic function which may
confound [11C]PHNO BPND. Patients classiﬁed with MDD (TBI-MDD)
had no history of depression prior to their injury and had no other
current DSM-IV diagnoses. All healthy controls and TBI patients clas-
siﬁed as having no history of depression (TBI-NON) had no current or
previous DSM-IV diagnoses.
2.2. Standard protocol approvals, registrations, and patient consents
This study was approved by the Westminster Research ethics com-
mittee. All participants gave written informed consent.
2.3. Neuropsychology
A neuropsychological test battery previously described to assess
cognitive impairment after TBI (Kinnunen et al., 2011) was performed
on patients and a control group. Tests included measures of processing
speed, executive function, pre-morbid intellectual ability and memory.
2.4. Psychiatric assessment
TBI patients were classiﬁed as having MDD or no depressive
symptoms based on the Structured Clinical Interview for DSM-IV-TR
AXIS I Disorders, Version I/NP (SCID; overseen by a qualiﬁed psy-
chiatrist, VR) (First et al., 2002). No other psychiatric illnesses were
identiﬁed in any of the patients. In addition, patients completed the
Beck Depression Inventory (BDI) (Beck and Beamesderfer, 1974) to
assess current severity of major depressive symptoms.
2.5. Imaging protocol
Patients and controls underwent a single PET scan acquired using a
Siemens Biograph 16 HI-REZ PET-CT scanner (Siemens Healthcare).
The radiotracer [11C]PHNO was administered as an intravenous bolus
over 30 s and dynamic PET data was acquired for 90min. Injected [11C]
PHNO did not exceed 3 μg total mass to avoid symptoms of nausea that
have previously been reported. Administration of [11C]PHNO below
3 μg have previously been used to eﬀectively quantify D2/D3 receptors
in vivo (Erritzoe et al., 2014). A low-dose computed tomography (CT)
image was acquired prior to administration of the radiotracer for at-
tenuation correction during PET reconstruction. Further information
about reconstruction of the dynamic PET images can be found in pre-
viously published literature (Searle et al., 2010). In summary, the PET
data were binned into 26 frames (8× 15 s, 3× 60 s, 5×2min,
5×5min, 5× 10min) and reconstructed using Fourier re-binning and
two-dimensional ﬁltered back projection with a ramp ﬁlter at Nyquist
cutoﬀ frequency. Image data were smoothed with a Gaussian ﬁlter
(5 mm full-width at half-maximum). Patients and controls who had PET
scanning had a standard high-resolution T1 MPRAGE scan (160 1-mm-
thick transverse slices, TR= 2300ms, TE=2.98ms, FA=9°, in-plane
resolution=1×1mm, matrix size= 256×256, ﬁeld of
view=25.6×25.6 cm), acquired for use in the co-registration of
parametric [11C]PHNO BPND images. Standard high-resolution T1 was
acquired using two Siemens 3T Verio MRI's (Siemens Healthcare).
For GM volume and DTI analyses, patients and a separate control
group were scanned using the same Siemens 3T Verio MRI (Appendix
ﬁg. A.1). Acquisition of diﬀusion weighted imaging for diﬀusion tensor
imaging analysis was performed on a 3T Veiro MRI using a 64-direction
protocol with b=1000 s/mm2 and four interleaved b=0 s/mm2, with
TE/TR 103/9500ms, 64 contiguous slices, FoV 256mm and voxel size
2mm3. Susceptibility-weighted imaging (SWI) and ﬂuid-attenuated
inversion recovery (FLAIR) to facilitate assessment of focal lesions in
patients was also acquired. No MRI analysis was performed across the
two scanners.
2.6. Imaging analysis
Non-displaceable binding potential (BPND) images of [11C]PHNO
were generated using a molecular imaging and kinetic analysis toolbox
(MIAKAT) (Gunn et al., 2016). The simpliﬁed reference tissue model
(SRTM) (Lammertsma and Hume, 1996) with cerebellar grey matter
(GM) as the reference region was used for generation of parametric D2/
D3 BPND images, as per previous research (Searle et al., 2010).
T1 images were segmented into GM and white matter (WM) using
SPM8. Tissue segmentations were then warped to a group template
using a diﬀeomorphic non-linear image registration procedure
(DARTEL) (Ashburner, 2007). The group template was then registered
to Montreal Neurological Institute (MNI152) space using an aﬃne re-
gistration. Parametric [11C]PHNO BPND images were co-registered to
their relative T1 images using a rigid-body registration and then warped
into MNI152 space using the template registration ﬂow-ﬁelds obtained
from the DARTEL registration. Normalized BPND images were then
masked using a thresholded GM template and smoothed (8mm full-
width at half-maximum). To investigate the presence of GM atrophy,
GM tissue segmentations of patients and controls acquired on the same
scanner were warped to a group template using DARTEL and standar-
dized to MNI152 space for use in voxel-based morphometry (VBM)
(Ashburner and Friston, 2000).
Two types of analysis were performed to investigate [11C]PHNO
BPND: voxelwise analysis in images registered into standard MNI152
space and region-of-interest (ROI) analysis performed in subject T1
space. [11C]PHNO BPND values were extracted using an anatomical
atlas previously developed for use in regional analysis of [11C]PHNO
data (Tziortzi et al., 2011). The atlas was ﬁrst aﬃne-registered from
MNI152 space to the group template. Next, the atlas was inversely
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warped to each subject's native T1 using DARTEL and subject-speciﬁc
ﬂow-ﬁelds. Native-space anatomical maps were visually assessed to
ensure accuracy of registration. To further improve accuracy, ROIs were
intersected with the subject's 30% thresholded GM tissue probability
map (p > .3) to extract mean regional BPND values. Eight ROIs were
selected a priori based on their involvement in the dopaminergic
system, prominence of dopamine D2/D3 receptors and involvement in
cognitive and emotional processing. The ROIs selected were; ac-
cumbens, amygdala, caudate, hypothalamus, pallidum, putamen, tha-
lamus and substantia nigra. Although the ventral tegmental area (VTA)
plays an important role in dopaminergic functioning within the brain,
the size of this region and diﬃculty to accurately delineate the VTA
could lead to unreliable results. We therefore did not explore this region
in this analysis given the relatively low spatial resolution of PET and
potential partial volume eﬀects. Lesions present on T1 and FLAIR se-
quences in patients were manually segmented and excluded from ROI
and voxelwise analysis.
Diﬀusion tensor imaging was used to derive FA as a measure of
white matter microstructure. Fractional anisotropy maps were con-
structed using the DTI-TK toolbox (Zhang et al., 2007) and subse-
quently skeletonized for ROI analysis using TBSS (Smith et al., 2006).
The mean FA for each ROI was extracted across patients and controls to
investigate group diﬀerences and any relationship to [11C]PHNO BPND.
To examine the eﬀect of TBI on dopaminergic neurons, the nigrostriatal
projections (nigro-caudate, nigro-putamen, nigro-accumbens) were in-
cluded in our analyses. A map of the area through which the nigros-
triatal tract passes, as well as nigro-caudate, nigro-putamen and nigro-
nucleus accumbens components of this map, was created using 100
subjects from the Human Connectome Project (HCP) (Van Essen et al.,
2013). Fiber-tracking was performed in both directions between the left
and right substantia nigra and the corresponding nucleus accumbens,
putamen and caudate using the MRtrix package (Tournier et al., 2012).
Three thousand tracks were performed with maximum angle between
successive steps limited to 45°. A probability mask based on the per-
centage of tracks passing through each voxel was created for each in-
dividual and thresholded at 5%. All masks were binarised and masks
from the two directions of tracking were combined. A group probabil-
istic mask that was then thresholded at 25% to create a group mask.
The FA values for controls and patients were then extracted using
these tract masks to assess any relationships between white matter in-
tegrity and binding potentials. We also investigated the impact of TBI
upon limbic connections using two tracts (the cingulum and uncinate
fasciculus) from the Johns Hopkins University (JHU) WM atlas. These
tracts were selected as they have previously been implicated in non-
traumatic MDD (Zhang et al., 2012). Finally, we measured FA from the
anterior thalamic projection as a control region which is commonly
aﬀected after injury.
2.7. Statistical analysis
Statistical analysis was performed in two stages. Firstly, all TBI
patients were compared to controls to identify TBI-related diﬀerences.
Secondly, to investigate the relationship between TBI and the presence
of MDD, TBI patients were subdivided into TBI-MDD and TBI-NON
groups and compared with controls.
2.7.1. TBI patients and controls
Neuropsychological test performance between TBI patients and
controls was assessed using independent samples t-tests and Mann
Whitney-U tests using statistical software R, version 3.2.3. Voxelwise
diﬀerences in BPND between patients and controls were investigated
using non-parametric permutation tests in FSL using 10,000 permuta-
tions and including age and gender as covariates. Results were cluster
corrected using threshold-free cluster enhancement and corrected for
multiple comparison using family-wise error correction (p < .05). A
repeated measures ANOVA was performed for ROI analysis of BPND
across groups, including a group-by-ROI interaction term.
Complementary pairwise comparisons with Bonferroni correction or
one-way ANOVAs were performed to determine the drivers of any
signiﬁcant group-by-ROI interactions, again using R version 3.2.3.
Previous literature has demonstrated age-related diﬀerences in dopa-
minergic levels (Kaasinen and Rinne, 2002) as well as time-dependent
changes to dopaminergic function after TBI (Wagner et al., 2005).
Therefore, Pearson's correlation was used to determine if there was a
relationship between age, time since injury and regional [11C]PHNO
BPND.
GM volume diﬀerences between patients and controls were assessed
using voxel-based morphometry (VBM). VBM was performed using the
standardized GM tissue segmentations, using non-parametric permu-
tation tests in FSL with 10,000 permutations. Age, gender and in-
tracranial volume (ICV) were covariates in the analysis. Previous re-
search has demonstrated reductions to SN volume after TBI and its
relationship to dopaminergic changes (Jenkins et al., 2016). We
therefore also examined SN volume and it's relationship to [11C]PHNO
BPND. GM volume was measured in the SN of patients and controls by
intersecting a SN mask with standardized GM tissue segmentations. An
independent samples t-test was used to examine group diﬀerences,
corrected for age and ICV. SN volume was also correlated to [11C]PHNO
BPND across the eight ROIs using Pearson's correlation to investigate
any relationship.
2.7.2. Comparison of MDD, non-MDD and healthy controls
Further investigation into the role of TBI in the development of
MDD was assessed by comparing data across three groups (TBI-MDD,
TBI-NON and healthy controls). Repeated measures ANOVA were per-
formed across the three groups to examine group-by-ROI interactions.
Subsequent one-way ANOVAs were performed to assess the group dif-
ferences across regions.
3. Results
Twelve TBI patients (mean age 36.9 years, SD 9.9) were recruited
(Table 1). Six patients were classiﬁed as having MDD (mean age
39.5 years, SD 11.2) and six as non-MDD (mean age 34.7 years, SD 9.7).
For comparison of PET, a group of 26 healthy controls (mean age
35.9 years, SD 6.9) were included and a second group of 32 healthy
controls (mean age 37.6 years, SD 9.1) were included for comparison of
DTI, GM atrophy and neuropsychological measures.
A consultant neuroradiologist reviewed the structural MRI scans. Six
TBI patients had no focal lesions as deﬁned on T1 and FLAIR. The re-
maining six patients had focal lesions in the frontal (n=3) and tem-
poral (n=3) lobes (Fig. A.2). No focal lesions were present in sub-
cortical areas. Microbleeds as deﬁned on SWI, were present in ﬁve
patients. Of these ﬁve patients, one was found to have microbleeds
subcortically in the lentiform nucleus (Table 1).
TBI patients showed impairments on a number of neuropsycholo-
gical tests compared to age-matched controls. Performance was sig-
niﬁcantly poorer on tasks involving processing speed and executive
function (Table 2). There were no diﬀerences in pre-morbid intellectual
ability across the two groups. Performance on neuropsychological tests
did not diﬀer between TBI-MDD and TBI-NON patients.
3.1. TBI is associated with reduced caudate D2/D3 receptor availability
Individual [11C]PHNO BPND images are shown in Fig. 1. As ex-
pected, [11C]PHNO BPND was concentrated in D2/D3 rich structures
such as the striatum, although there was a patchy reduction apparent in
many patients. Voxelwise comparison of [11C]PHNO BPND revealed
areas of lower BPND in the caudate and thalamus of TBI patients
(Fig. 2A.). No regions showed increased BPND in TBI patients compared
to controls.
A conﬁrmatory ROI analysis was performed. Repeated measures
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ANOVA of BPND across the regions showed a signiﬁcant group-by-re-
gion interaction (F(7,245)= 6.4, p= .001), Greenhouse-Geisser cor-
rected. This interaction resulted from a speciﬁc reduction of BPND in the
caudate for TBI patients (p= .025) (Fig. 2B). Age and time since injury
did not correlate with regional BPND.
3.2. Major depressive disorder (MDD) following TBI is associated with
altered D2/D3 receptor availability
We assessed the relationship between [11C]PHNO binding and MDD
using a ROI approach (Fig. 3). Repeated measures ANOVA across the
three groups (TBI-MDD, TBI-NON and controls) showed a signiﬁcant
group-by-region interaction (F(14,238)= 4.104, p= .001), Green-
house-Geisser corrected. Complementary one-way ANOVAs revealed
that this interaction was the result of a signiﬁcant main eﬀect of group
in the caudate (F(2,34)= 5.398, p= .009), with post-hoc t-tests in-
dicating signiﬁcantly reduced binding in the caudate of TBI-MDD pa-
tients compared to controls (p= .014). A signiﬁcant eﬀect of group was
also present in the amygdala (F(2,34)= 5.81, p= .007), with post-hoc
t-tests revealing increased binding for TBI-NON patients compared to
controls (p= .005). There were no signiﬁcant diﬀerences in [11C]PHNO
BPND between the two TBI patient groups. Age and time since injury did
not correlate with regional BPND across the three groups. TBI-MDD
patients had signiﬁcantly higher BDI scores (mean=21.83), U= 29,
p= .045, than TBI-NON patients (mean=7.17). However, there was
no correlation between BDI scores and BPND in any region.
3.3. Control analyses for positron emission tomography results
As expected, patients had reduced GM volume in the frontal lobes,
striatum and cerebellum. As cerebellar GM is used as the reference
tissue region for modeling [11C]PHNO BPND this might potentially
confound our analysis. However, there were no group diﬀerences in the
standard uptake values (SUVs) in the cerebellum used in the calculation
of parametric [11C]PHNO BPND images between patients and controls (t
(34.557)= 0.852, p= .399) or across the three groups (F
(2,35)= 0.637, p= .535) (Fig. A.3). Reduced GM volume observed in
the striatum of patients may contribute to reduced [11C]PHNO uptake.
However, linear regression revealed no relationship between GM vo-
lume and [11C]PHNO BPND in regions within the striatum of patients orT
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Table 2
Neuropsychology performance for TBI patients and controls.
Neuropsychological test Controls (n=32) Patients (n=12) p
Processing speed
Stroop colour naming 27.56 ± 4.72 34.18 ± 8.55 .015⁎
Stroop word reading 20.44 ± 4.48 26.64 ± 8.05 .016⁎
Trail making A 19.62 ± 7.13 30.27 ± 17.04 .034⁎
Executive function
Trail making B 44.84 ± 22.67 69.82 ± 37.90 .030⁎
Stroop inhibition 49.97 ± 11.63 50.36 ± 11.78 .462
Stroop inhibition switching 55.59 ± 15.42 66.0 ± 22.14 .078
Trail making test B-A 25.28 ± 19.02 39.55 ± 25.35 .046⁎
Memory
WMS-III LM1 Immediate recall 50.25 ± 8.44 48.18 ± 11.16 .292
WMS-III LM2 delayed recall 32.38 ± 7.024 33.5 ± 8.49 .645
Peoples test immediate recall 28.44 ± 5.75 27.18 ± 9.83 .348
Peoples test delayed recall 10.12 ± 2.90 9.64 ± 2.73 .310
Intellectual ability
WTAR scaled score 114.9 ± 8.30 107.3 ± 19.91 .240
WASI matrix reasoning 28.88 ± 4.98 28.73 ± 3.20 .910
Mean and SD of neuropsychological test scores for patients and controls are
presented. WMS-II=Wechsler memory scale, second edition. LM=Logical
memory. WTAR=Wechsler adult test of reading, WASI=Wechsler abbreviated
scale of intelligence.
⁎ p < .05.
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in any other ROI's included in our analysis (p > .3).
3.4. Nigro-caudate tract fractional anisotropy correlates with D2/D3
receptor availability in the caudate
We have previously shown relationships between diﬀusion MRI
measures in white matter through which the nigrostriatal pathways
pass and dopamine transporter imaging (DAT) (Jenkins et al., 2018).
Therefore, to explore the reasons for abnormal [11C]PHNO BPND we
investigated their relationship to these diﬀusion metrics. Within TBI
patients, linear regression revealed a signiﬁcant relationship between
nigro-caudate tract FA and [11C]PHNO BPND in the caudate
(b=−0.04, SE= 0.01, t=−3.12, p= .01), such that greater FA re-
lated to lower [11C]PHNO caudate binding (Fig. 4). There was no re-
lationship between [11C]PHNO BPND in the accumbens or putamen and
FA within the projections to these structures from the substantia nigra.
Despite these relationships there were no signiﬁcant diﬀerences in FA
between controls and patients in the three nigrostriatal pathways.
3.5. Substantia Nigra volume does not correlate with D2/D3 receptor
availability in patients
We also investigated whether reductions to dopaminergic nuclei
volume were present in patients and whether this related to reduced
[11C]PHNO BPND in the caudate of TBI patients. There was no sig-
niﬁcant diﬀerence between TBI patients and controls for SN volume,
corrected for age and ICV, although this approached signiﬁcance
(p= .065). We did not ﬁnd a relationship between SN volume and
caudate [11C]PHNO BPND in patients.
3.6. TBI patients with major depressive disorder have signiﬁcantly reduced
FA in white matter tracts that connect the limbic system
We next investigated whether TBI patients with MDD have greater
evidence of axonal injury compared to TBI-NON patients and controls.
One-way ANOVAs performed across the three groups (TBI-MDD, TBI-
NON and controls) revealed a signiﬁcant main eﬀect of group for the
cingulum (F(2,39)= 10.83, p < .001) which was driven by sig-
niﬁcantly reduced FA in TBI-MDD patients (p= .007) and TBI-NON
patients (p= .001) compared to controls. There was also a main eﬀect
of group in the uncinate fasiculus (F(2.39)= 4.121, p= .02), driven by
signiﬁcantly reduced FA in TBI-MDD patients compared to controls
(p= .03). There were no signiﬁcant diﬀerences between the two pa-
tient groups (Fig. 5).
Fig. 1. [11C]PHNO PET BPND images of TBI patients and two representative healthy controls.
Figure illustrates parametric [11C]PHNO BPND images for TBI patients and two healthy controls (CON). Scans are annotated for patients with (TBI-MDD) and without
depression (TBI-NON) and age. [11C]PHNO BPND is shown in the colour bar. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
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4. Discussion
Here we present the ﬁrst use of [11C]PHNO PET to investigate do-
paminergic abnormalities following TBI. We show that [11C]PHNO
BPND is lower in the caudate after TBI, and that this abnormality is more
prominent in patients with MDD. In addition, greater binding was seen
in non-depressed patients in the amygdala compared to controls, sug-
gesting that compensatory changes in the dopamine system might be
protective against the development of MDD after TBI.
[11C]PHNO binding reﬂects the availability of D2 and D3 receptors
and can be attributed to receptor density as well as endogenous
dopamine levels (Schotte et al., 1996). Although [11C]PHNO pre-
ferentially binds to D3 receptors with a 20 fold selectivity over D2 re-
ceptors (Gallezot et al., 2012), binding in regions containing both re-
ceptors will represent mixed D2 and D3 signal. The relative
contributions of D2 and D3 receptors to [11C]PHNO signal within a
region is an important consideration when interpreting our ﬁndings.
Blockade studies using D3-speciﬁc antagonists have illustrated that D2
receptors are predominantly expressed in the caudate (Searle et al.,
2010; Tziortzi et al., 2011). Therefore, reductions in caudate binding
seen in TBI patients may primarily reﬂect reduced availability of D2
receptors after TBI. In contrast, the amygdala consists of a mixture of
D2 and D3 receptors, as shown by human post-mortem studies (Murray
et al., 1994; Gurevich and Joyce, 1999). Given the high aﬃnity of [11C]
PHNO for D3 receptors, increased binding within the amygdala is likely
to indicate increased expression of D3 receptors in this region. Baseline
and blockade scans using a D3-speciﬁc antagonist to quantify the re-
lative D2 and D3 contributions to [11C]PHNO signal in the amygdala
would help to further disentangle the eﬀects of TBI on D2 and D3 re-
ceptors in our patients.
Our ﬁndings extend previous work demonstrating dopaminergic
abnormalities after TBI (Donnemiller et al., 2000; Wagner et al., 2014).
Animal models of TBI show that dopaminergic abnormalities are
common and the behavioural consequences can be treated with dopa-
mine re-uptake inhibitors (Wagner et al., 2009). In humans, TBI fre-
quently disrupts dopaminergic pathways through a variety of me-
chanisms. Focal brainstem damage can directly damage brainstem
dopaminergic nuclei, and traumatic axonal injury can damage their
white matter projections (Jenkins et al., 2018). The eﬀect of these
Fig. 2. Comparison of [11C]PHNO BPND between TBI patients and controls.
Results of the two statistical comparisons of [11C]PHNO BPND between TBI patients (PAT) and controls (CON). (A) Voxelwise results showing areas of signiﬁcant
reduction in [11C]PHNO BPND in patients compared to controls (p < .05). (B) Region-of-interest analysis of BPND between TBI patients and controls. Error bars
represent 95% conﬁdence interval. ⁎p < .05 (Bonferroni corrected).
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Fig. 3. Region-of-interest [11C]PHNO BPND between healthy controls and pa-
tients with and without MDD.
Results of region-of-interest analysis of [11C]PHNO BPND between healthy
controls (CON) and TBI patients with (TBI-MDD) and without (TBI-NON) de-
pression. Error bars represent 95% conﬁdence intervals. ⁎p < .05.
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changes has consistently been observed as a reduction in DAT in the
striatum after TBI (Wagner et al., 2005; Donnemiller et al., 2000;
Wagner et al., 2014). DAT is the main regulator of synaptic dopamine
levels and this change is likely to be due to a compensatory down-
regulation in response to reduced synaptic dopamine levels. Although
we did not ﬁnd evidence of axonal injury in dopaminergic projections,
nigro-caudate FA was related to dopaminergic abnormalities in the
caudate of TBI patients, suggesting an important role for dopaminergic
projections and the compensatory changes to the dopaminergic path-
ways observed after TBI.
A small number of studies on the eﬀects of TBI on dopamine re-
ceptor distributions have been conducted but D3 receptors have not
previously been investigated. Animal studies have not provided evi-
dence for chronic changes in D2 receptors after TBI (Wagner et al.,
2005). However in humans, chronic changes have been reported.
Donnemiller and colleagues reported reductions of striatal D2 receptor
binding using the SPECT tracer 123I-IBZM in patients who also had re-
ductions of DAT in this region (Donnemiller et al., 2000). In contrast,
higher D2 receptor binding has been seen in the ventral striatum using
the PET ligand [11C]raclopride (Wagner et al., 2014). Our results re-
plicate the ﬁnding of reduced D2 receptor binding in the caudate, but
also provide some evidence of variability in the eﬀect of TBI on dopa-
mine receptors as [11C]PHNO binding was increased in patients without
MDD in the amygdala. These results suggest multiple factors may
A
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Fig. 4. Nigro-caudate tract fractional anisotropy and caudate [11C]PHNO BPND in TBI patients.
(A) Probabilistic map of nigro-caudate tract derived from tractography of 100 healthy controls from the human connectome project. Colour bar showing fractional
anisotropy (FA) (B) Relationship between nigro-caudate tract FA and caudate [11C]PHNO BPND in TBI patients.
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inﬂuence levels of D2 and D3 receptors following TBI which require
further exploration.
Compensatory reductions in DAT could lead to a direct reduction in
post-synaptic D2 receptors, whereas increased binding in the amygdala
might be due to a compensatory upregulation of receptors in response
to reduced synaptic dopamine levels. However, changes to endogenous
dopamine levels might also contribute to the alterations in [11C]PHNO
BPND seen in our patients without a direct relationship to receptor
density changes. Reductions in DAT can increase synaptic dopamine
levels following TBI. Increased synaptic dopamine levels may provide
greater competition with [11C]PHNO to bind to D2/D3 receptors thus
leading to decreased [11C]PHNO BPND within these regions. Extending
the current work to include quantiﬁcation of DAT in addition to [11C]
PHNO BPND would provide a greater understanding of the mechanisms
behind changes in [11C]PHNO BPND.
Dopaminergic abnormalities caused by TBI may be related to post-
traumatic depression. In keeping with this possibility, we observed
patterns of [11C]PHNO binding in patients with and without post-
traumatic depression, which suggest the potential involvement of do-
paminergic abnormalities in post-traumatic depression. Abnormally
low [11C]PHNO binding was only observed in TBI-MDD patients com-
pared to controls when patients were grouped by psychiatric status,
suggesting a potential role for altered dopamine function in the caudate
in post-traumatic depression. In individuals with non-traumatic MDD,
lower striatal DAT has been observed (Meyer et al., 2001) whilst in-
creases in D2 receptor binding have been associated with recovery from
clinical depression over time (Larisch et al., 1997). A relationship
between dopaminergic abnormalities and depressive symptoms has also
been observed in other neurological conditions. Depression is com-
monly seen in Parkinson's disease (PD), where striatal DAT and D2
receptor levels are often reduced (Vriend et al., 2014; Antonini et al.,
1997). Depressed patients with PD have also been shown to have sig-
niﬁcantly reduced DAT binding in the caudate compared to non-de-
pressed PD patients (Remy et al., 2005). Similarly, in Huntington's
disease (HD) (a disease associated with neuronal cell loss in the caudate
(Roth et al., 2005) and dopaminergic abnormalities), many patients
develop depressive illness (Paulsen et al., 2005).
TBI patients without MDD showed higher [11C]PHNO binding in the
amygdala compared to controls, which might indicate a compensatory
change in D3 receptor expression that protects against the development
of depression after TBI. However, this must be considered carefully
given the small group sizes and no signiﬁcant diﬀerences being detected
between TBI-MDD and TBI-NON patient groups. Nevertheless, the
amygdala is widely implicated in the regulation of mood and aﬀect. In
non-TBI depressed patients, pathophysiological changes to this region
have included alterations in resting glucose metabolism, volume and
dopamine transmission (Drevets, 2003; Klimek et al., 2002). Dopamine
plays an important role in the modulation of the amygdala and its re-
sponse to stimuli (Kienast et al., 2008). Interestingly, animal models
have demonstrated that antidepressant treatments (such as tricyclic
antidepressants) selectively increase D3 receptor expression (Lammers
et al., 2000) and D3-receptor agonists such as pramipexole have anti-
depressant properties in both humans and animal models (Willner,
1983; Goldberg et al., 1999). It is conceivable that D3 receptor
Fig. 5. Fractional anisotropy in limbic tracts across patients and controls.
(A) Results of regional FA analysis in the uncinate fasciculus across TBI patients classiﬁed with (TBI-MDD) or without (TBI-NON) depression and healthy controls
(CON). (B) Results of regional FA analysis in the cingulum across the three groups. Tracts are represented in yellow in brain images. ⁎p < .05, ⁎⁎p < .01.
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upregulation after TBI might provide similar beneﬁts to antidepressant
treatment and that measuring D2/D3 receptor levels might inform the
choice of eﬀective anti-depressant medication after TBI.
We also found evidence for abnormalities in white matter connec-
tions within the limbic system, with more widespread damage seen in
depressed patients. Diﬀusion abnormalities were seen in the cingulum
and uncinate fasciculi bilaterally. These white matter tracts connect
nodes in the limbic system and similar diﬀusion abnormalities in these
tracts have previously been observed in patients with non-traumatic
depression (Zhang et al., 2012; Keedwell et al., 2012). Damage to the
uncinate fasciculus connections were only seen in depressed TBI pa-
tients, suggesting that damage to the connections between the pre-
frontal cortex and amygdala/hippocampal gyrus may be an important
factor in the development of post-traumatic depression.
There are a number of potential limitations to our work. Firstly, as
expected, there was evidence of post-traumatic atrophy in some brain
regions. It is possible that this might have inﬂuenced our PET results.
However, this is unlikely to be a major inﬂuence on our results as there
was no relationship between regional volume and binding in either the
caudate or any other ROI. In addition, cerebellar SUVs were similar in
the control and patient groups indicating that there was not a sys-
tematic bias between the groups in our reference regions. Secondly, we
focused on studying D2/D3 dopaminergic receptors. It is possible to
provide a more complete description of post-traumatic dopaminergic
abnormalities and future research would beneﬁt from measuring ad-
ditional factors such as DAT levels in conjunction with [11C]PHNO
binding. In addition, we used an automated atlas method to derive
ROIs. This process may be susceptible to noise due to misalignment in
smaller subcortical regions compared to manual delineation. However,
we used an advanced DARTEL registration method that has previously
been used for PET data and has superior registration to earlier non-
linear techniques.
Our study had small sample sizes within our TBI-MDD and TBI-NON
patient groups, which might have impacted on the power to detect
diﬀerences. Hence, our ﬁndings should be viewed as preliminary evi-
dence for the role of dopaminergic changes in TBI-MDD. We did not
observe any signiﬁcant diﬀerences between the two TBI groups but did
identify diﬀerent patterns of altered [11C]PHNO BPND when comparing
each group to healthy controls. Future studies would beneﬁt from larger
group sizes to determine whether there are distinct diﬀerences between
TBI-MDD and TBI-NON patients that we were underpowered to detect.
This would help to further clarify whether the observed patterns of
altered binding across the TBI groups are speciﬁc to psychiatric out-
comes. Although the sample sizes are small between these groups, our
ﬁndings suggest some potentially interesting D2/D3 regions to explore
further in much larger patient groups.
5. Conclusions
In conclusion, we provide evidence of altered D2/D3 receptor
binding after TBI, using [11C]PHNO PET for the ﬁrst time in this patient
population. Patterns of D2/D3 receptor abnormalities in clinically de-
pressed and non-depressed TBI patients varied when compared to
controls. Lower caudate binding supports previous ﬁndings of D2 ab-
normalities after TBI (Jenkins et al., 2018) and provide a potential
mechanistic link between altered dopaminergic function in the caudate
and the development of post-traumatic depression. These ﬁndings are
preliminary, and future research extending this work using larger
sample sizes is recommended.
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